Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
110 hedge funds and large institutions have $118M invested in Lumos Pharma, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 34 closing their positions.
104% more call options, than puts
Call options by funds: $4.33M | Put options by funds: $2.12M
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
14% less funds holding
Funds holding: 128 → 110 (-18)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
67% less capital invested
Capital invested by funds: $358M → $118M (-$240M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.16M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$6.88M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$5.86M |
| 5 |
CCI
Columbus Circle Investors
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.4M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.13M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.8M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$4.62M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.6M |
LUMO Hedge Fund Activity: Q2 2017 in Review
110 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2017, worth a combined $118M — down 67% from $358M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LUMO and 16 opened new positions — a net loss of 18 holders — while 34 trimmed existing stakes and 38 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $15M. The largest seller was Franklin Resources, exiting entirely with an estimated $12.4M sold.
- 110 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2017, down from 128 in Q1 2017.
- Funds reported $118M of Lumos Pharma, Inc. Common Stock stock for Q2 2017, down 67% quarter-over-quarter.
- 16 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2017 and 34 closed out, a net change of -18 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2017 was Great Point Partners, an estimated $15M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2017 was Franklin Resources, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2017.